234 related articles for article (PubMed ID: 37877845)
1. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
3. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
4. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
5. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
[TBL] [Abstract][Full Text] [Related]
7. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
Fowlkes AL; Yoon SK; Lutrick K; Gwynn L; Burns J; Grant L; Phillips AL; Ellingson K; Ferraris MV; LeClair LB; Mathenge C; Yoo YM; Thiese MS; Gerald LB; Solle NS; Jeddy Z; Odame-Bamfo L; Mak J; Hegmann KT; Gerald JK; Ochoa JS; Berry M; Rose S; Lamberte JM; Madhivanan P; Pubillones FA; Rai RP; Dunnigan K; Jones JT; Krupp K; Edwards LJ; Bedrick EJ; Sokol BE; Lowe A; McLeland-Wieser H; Jovel KS; Fleary DE; Khan SM; Poe B; Hollister J; Lopez J; Rivers P; Beitel S; Tyner HL; Naleway AL; Olsho LEW; Caban-Martinez AJ; Burgess JL; Thompson MG; Gaglani M
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(11):422-428. PubMed ID: 35298453
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
Riefolo F; Castillo-Cano B; Martín-Pérez M; Messina D; Elbers R; Brink-Kwakkel D; Villalobos F; Ingrasciotta Y; Garcia-Poza P; Swart-Polinder K; Souverein P; Saiz LC; Bissacco CA; Leache L; Tari M; Crisafulli S; Grimaldi L; Vaz T; Gini R; Klungel O; Martín-Merino E
Vaccine; 2023 Nov; 41(47):7007-7018. PubMed ID: 37858451
[TBL] [Abstract][Full Text] [Related]
11. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.
Baum U; Poukka E; Leino T; Kilpi T; Nohynek H; Palmu AA
BMC Infect Dis; 2022 Nov; 22(1):816. PubMed ID: 36335289
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021.
van Ewijk CE; Kooijman MN; Fanoy E; Raven SF; Middeldorp M; Shah A; de Gier B; de Melker HE; Hahné SJ; Knol MJ
Euro Surveill; 2022 Nov; 27(45):. PubMed ID: 36367011
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
16. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
[TBL] [Abstract][Full Text] [Related]
19. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
